Metastatic Colorectal Cancer Treatment

If you or someone you love has been diagnosed with metastatic colorectal cancer, one of the first questions may be: what treatment comes next? There isn’t one treatment that works for everyone. Instead, doctors look at several factors, including where the cancer is located, how quickly it is growing, your symptoms and overall health, and, […]

Discover how Y90 radioembolization is redefining success for colorectal liver metastases. Learn about treatment outcomes, survival rates, and clinical options.

Discover why MSI-H status is a game changer for colorectal cancer treatment. Learn how immunotherapy, like checkpoint inhibitors, improves outcomes for patients.

If you or a loved one has been diagnosed with colorectal cancer, you may have heard your care team mention “biomarker testing” or “molecular profiling.” These tests look at the specific genetic features of your tumor and the results can directly shape which treatments are most likely to work for you. Three of the most […]

When colorectal cancer (CRC) spreads to the lining of the abdomen (the peritoneum), treatment becomes more complex. For some patients with metastatic colorectal cancer (mCRC) involving the peritoneum, cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) may be considered as part of treatment. Research has helped establish CRS as a potential option for […]

In this expert Q&A, MD Anderson’s Dr. Scott Kopetz explains when surgery may still play a role in metastatic colorectal cancer (mCRC), how disease develops, and why biomarker testing at diagnosis is so important for guiding treatment decisions. Watch the full webinar 1) Is surgery a possible treatment route for patients with mCRC? Dr. Scott […]

For people living with HER2-positive metastatic colorectal cancer (CRC), treatment options can feel limited, especially when standard chemotherapy stops working. But new research presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting offers encouraging news: a targeted therapy called trastuzumab deruxtecan (Enhertu) may help patients live longer than standard chemotherapy, particularly when […]